{"id":4173,"date":"2024-03-18T06:01:36","date_gmt":"2024-03-18T13:01:36","guid":{"rendered":"https:\/\/grail.com\/?post_type=press-release&#038;p=4173"},"modified":"2024-03-18T06:06:10","modified_gmt":"2024-03-18T13:06:10","slug":"grail-announces-novel-risk-classification-test-to-be-used-in-lung-cancer-study","status":"publish","type":"press-release","link":"https:\/\/grail.com\/press-releases\/grail-announces-novel-risk-classification-test-to-be-used-in-lung-cancer-study\/","title":{"rendered":"GRAIL Announces Novel Risk Classification Test to be Used in Lung Cancer Study"},"content":{"rendered":"\n<p class=\"base-block\"><strong>MENLO PARK, Calif. and CAMBRIDGE, UK, Mar. 18, 2024<\/strong> \u2014 GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today that participants from Japan, via a collaboration with AstraZeneca (LSE\/STO\/Nasdaq:AZN), will have their samples tested using GRAIL\u2019s novel risk classification test on its Methylation Platform. This assay has been validated for recurrence risk classification in newly diagnosed Stage I lung adenocarcinoma.<\/p>\n\n\n\n<p class=\"base-block\">GRAIL\u2019s Methylation Platform enables tissue-free, blood-based cancer detection that can be customized for a suite of precision applications across hematological and solid tumors, including risk stratification, molecular subtyping, and molecular response. This study with AstraZeneca aims to demonstrate the test\u2019s capability to deliver results within 10 days without the need for tumor tissue, supporting use in future global pharmaceutical clinical trials.<\/p>\n\n\n\n<p class=\"base-block\">\u201cThe development of this risk classification test as part of GRAIL\u2019s clinical oncology portfolio is a significant milestone in our ongoing commitment to support patient care with novel, non-invasive tests for early detection and beyond,\u201d said Jeffrey Venstrom, MD, Chief Medical Officer at GRAIL. \u201cGRAIL\u2019s tissue-free, blood-only methodology is designed to aid in clinical trial selection with potential for customizable diagnostic approaches that can enable precision oncology.\u201d&nbsp;<\/p>\n\n\n\n<p class=\"base-block\">In 2022, GRAIL <a href=\"https:\/\/grail.com\/press-releases\/grail-announces-strategic-collaboration-with-astrazeneca-to-develop-companion-diagnostic-tests-to-enable-the-treatment-of-early-stage-cancer\/\">announced<\/a> a broad strategic collaboration with AstraZeneca to develop and commercialize companion diagnostic (CDx) assays for use with AstraZeneca\u2019s therapies.<\/p>\n\n\n\n<p class=\"base-block\">In December 2023, GRAIL <a href=\"https:\/\/grail.com\/press-releases\/validation-data-on-a-novel-prognostic-test-developed-by-grail-in-stage-i-lung-cancer-presented-at-north-america-conference-on-lung-cancer\/\">announced<\/a> the analytical and clinical validation of a novel prognostic test in Stage I lung adenocarcinoma.<\/p>\n\n\n\n<p class=\"base-block\"><strong>About GRAIL<\/strong><br>GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. GRAIL, LLC, is a subsidiary of Illumina, Inc. (NASDAQ:ILMN) currently held separate from Illumina Inc. under the terms of the Interim Measures Order of the European Commission.<\/p>\n\n\n\n<p class=\"base-block\">For more information, please visit&nbsp;<a href=\"https:\/\/www.grail.com\/\">grail.com<\/a>.<\/p>\n\n\n\n<p class=\"base-block\"><strong>Laboratory\/Test Information<\/strong><br>GRAIL\u2019s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. GRAIL\u2019s clinical laboratory is regulated under CLIA to perform high-complexity testing. GRAIL\u2019s current product offerings have not been cleared or approved by the U.S. Food and Drug Administration.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MENLO PARK, Calif. and CAMBRIDGE, UK, Mar. 18, 2024 \u2014 GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today that participants from Japan, via a collaboration with AstraZeneca (LSE\/STO\/Nasdaq:AZN), will have their samples tested using GRAIL\u2019s novel risk classification test on its Methylation Platform. This [&hellip;]<\/p>\n","protected":false},"featured_media":2753,"parent":0,"menu_order":0,"template":"","format":"standard","meta":{"_acf_changed":true,"footnotes":""},"class_list":["post-4173","press-release","type-press-release","status-publish","format-standard","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>GRAIL Announces Novel Risk Classification Test to be Used in Lung Cancer Study - GRAIL<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/grail.com\/press-releases\/grail-announces-novel-risk-classification-test-to-be-used-in-lung-cancer-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GRAIL Announces Novel Risk Classification Test to be Used in Lung Cancer Study - GRAIL\" \/>\n<meta property=\"og:description\" content=\"MENLO PARK, Calif. and CAMBRIDGE, UK, Mar. 18, 2024 \u2014 GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today that participants from Japan, via a collaboration with AstraZeneca (LSE\/STO\/Nasdaq:AZN), will have their samples tested using GRAIL\u2019s novel risk classification test on its Methylation Platform. This [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/grail.com\/press-releases\/grail-announces-novel-risk-classification-test-to-be-used-in-lung-cancer-study\/\" \/>\n<meta property=\"og:site_name\" content=\"GRAIL\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/grailbio\/\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-18T13:06:10+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/grail.com\/wp-content\/uploads\/2022\/04\/GettyImages-168166178.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2121\" \/>\n\t<meta property=\"og:image:height\" content=\"1414\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@grailbio\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/grail.com\/press-releases\/grail-announces-novel-risk-classification-test-to-be-used-in-lung-cancer-study\/\",\"url\":\"https:\/\/grail.com\/press-releases\/grail-announces-novel-risk-classification-test-to-be-used-in-lung-cancer-study\/\",\"name\":\"GRAIL Announces Novel Risk Classification Test to be Used in Lung Cancer Study - GRAIL\",\"isPartOf\":{\"@id\":\"https:\/\/grail.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/grail.com\/press-releases\/grail-announces-novel-risk-classification-test-to-be-used-in-lung-cancer-study\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/grail.com\/press-releases\/grail-announces-novel-risk-classification-test-to-be-used-in-lung-cancer-study\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2022\/04\/GettyImages-168166178.jpg\",\"datePublished\":\"2024-03-18T13:01:36+00:00\",\"dateModified\":\"2024-03-18T13:06:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/grail.com\/press-releases\/grail-announces-novel-risk-classification-test-to-be-used-in-lung-cancer-study\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/grail.com\/press-releases\/grail-announces-novel-risk-classification-test-to-be-used-in-lung-cancer-study\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/grail.com\/press-releases\/grail-announces-novel-risk-classification-test-to-be-used-in-lung-cancer-study\/#primaryimage\",\"url\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2022\/04\/GettyImages-168166178.jpg\",\"contentUrl\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2022\/04\/GettyImages-168166178.jpg\",\"width\":2121,\"height\":1414,\"caption\":\"Getty\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/grail.com\/press-releases\/grail-announces-novel-risk-classification-test-to-be-used-in-lung-cancer-study\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/grail.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GRAIL Announces Novel Risk Classification Test to be Used in Lung Cancer Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/grail.com\/#website\",\"url\":\"https:\/\/grail.com\/\",\"name\":\"GRAIL\",\"description\":\"Detect cancer early, when it can be cured\",\"publisher\":{\"@id\":\"https:\/\/grail.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/grail.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/grail.com\/#organization\",\"name\":\"GRAIL, LLC\",\"url\":\"https:\/\/grail.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/grail.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/01\/cropped-favicon-G.png\",\"contentUrl\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/01\/cropped-favicon-G.png\",\"width\":512,\"height\":512,\"caption\":\"GRAIL, LLC\"},\"image\":{\"@id\":\"https:\/\/grail.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/grailbio\/\",\"https:\/\/x.com\/grailbio\",\"https:\/\/www.linkedin.com\/company\/grail-inc.\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GRAIL Announces Novel Risk Classification Test to be Used in Lung Cancer Study - GRAIL","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/grail.com\/press-releases\/grail-announces-novel-risk-classification-test-to-be-used-in-lung-cancer-study\/","og_locale":"en_US","og_type":"article","og_title":"GRAIL Announces Novel Risk Classification Test to be Used in Lung Cancer Study - GRAIL","og_description":"MENLO PARK, Calif. and CAMBRIDGE, UK, Mar. 18, 2024 \u2014 GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today that participants from Japan, via a collaboration with AstraZeneca (LSE\/STO\/Nasdaq:AZN), will have their samples tested using GRAIL\u2019s novel risk classification test on its Methylation Platform. This [&hellip;]","og_url":"https:\/\/grail.com\/press-releases\/grail-announces-novel-risk-classification-test-to-be-used-in-lung-cancer-study\/","og_site_name":"GRAIL","article_publisher":"https:\/\/www.facebook.com\/grailbio\/","article_modified_time":"2024-03-18T13:06:10+00:00","og_image":[{"width":2121,"height":1414,"url":"http:\/\/grail.com\/wp-content\/uploads\/2022\/04\/GettyImages-168166178.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@grailbio","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/grail.com\/press-releases\/grail-announces-novel-risk-classification-test-to-be-used-in-lung-cancer-study\/","url":"https:\/\/grail.com\/press-releases\/grail-announces-novel-risk-classification-test-to-be-used-in-lung-cancer-study\/","name":"GRAIL Announces Novel Risk Classification Test to be Used in Lung Cancer Study - GRAIL","isPartOf":{"@id":"https:\/\/grail.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/grail.com\/press-releases\/grail-announces-novel-risk-classification-test-to-be-used-in-lung-cancer-study\/#primaryimage"},"image":{"@id":"https:\/\/grail.com\/press-releases\/grail-announces-novel-risk-classification-test-to-be-used-in-lung-cancer-study\/#primaryimage"},"thumbnailUrl":"https:\/\/assets.grail.com\/wp-content\/uploads\/2022\/04\/GettyImages-168166178.jpg","datePublished":"2024-03-18T13:01:36+00:00","dateModified":"2024-03-18T13:06:10+00:00","breadcrumb":{"@id":"https:\/\/grail.com\/press-releases\/grail-announces-novel-risk-classification-test-to-be-used-in-lung-cancer-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/grail.com\/press-releases\/grail-announces-novel-risk-classification-test-to-be-used-in-lung-cancer-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/grail.com\/press-releases\/grail-announces-novel-risk-classification-test-to-be-used-in-lung-cancer-study\/#primaryimage","url":"https:\/\/assets.grail.com\/wp-content\/uploads\/2022\/04\/GettyImages-168166178.jpg","contentUrl":"https:\/\/assets.grail.com\/wp-content\/uploads\/2022\/04\/GettyImages-168166178.jpg","width":2121,"height":1414,"caption":"Getty"},{"@type":"BreadcrumbList","@id":"https:\/\/grail.com\/press-releases\/grail-announces-novel-risk-classification-test-to-be-used-in-lung-cancer-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/grail.com\/"},{"@type":"ListItem","position":2,"name":"GRAIL Announces Novel Risk Classification Test to be Used in Lung Cancer Study"}]},{"@type":"WebSite","@id":"https:\/\/grail.com\/#website","url":"https:\/\/grail.com\/","name":"GRAIL","description":"Detect cancer early, when it can be cured","publisher":{"@id":"https:\/\/grail.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/grail.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/grail.com\/#organization","name":"GRAIL, LLC","url":"https:\/\/grail.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/grail.com\/#\/schema\/logo\/image\/","url":"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/01\/cropped-favicon-G.png","contentUrl":"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/01\/cropped-favicon-G.png","width":512,"height":512,"caption":"GRAIL, LLC"},"image":{"@id":"https:\/\/grail.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/grailbio\/","https:\/\/x.com\/grailbio","https:\/\/www.linkedin.com\/company\/grail-inc.\/"]}]}},"_links":{"self":[{"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/press-release\/4173","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/press-release"}],"about":[{"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/types\/press-release"}],"version-history":[{"count":0,"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/press-release\/4173\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/media\/2753"}],"wp:attachment":[{"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/media?parent=4173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}